Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
Other

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

By The Northwire Desk — AI Analysis Nov 25, 2025 · 16:00 QNTM · 9 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma announced that CTV News’ investigative program W5 will air a three‑part series beginning today, focusing on the company’s $700 million stock‑market manipulation lawsuit against CIBC and RBC.
  • The release highlights the alleged “stock spoofing” that the company claims derailed its multiple‑sclerosis drug development and underscores its commitment to exposing such practices.
  • CEO Zeeshan Saeed reiterated the therapeutic promise of Lucid‑MS and the company’s goal of preventing similar market manipulation from affecting other firms and investors.

Key Details

  • The W5 series, hosted by journalist Jon Woodward, will debut Part One titled “Was a Canadian company’s multiple sclerosis research nearly derailed by ‘market manipulation’?” and is available on CTV News.
  • Quantum BioPharma is pursuing a USD $700 million lawsuit against two of Canada’s largest banks—CIBC and RBC—alleging illegal stock‑spoofing that impacted the company’s share price.
  • CEO Zeeshan Saeed said: “We thank W5 for their important investigation into the illegal, but little known, practice of stock spoofing… By shining a light on our experience with alleged stock market manipulation, we hope to prevent other companies, their shareholders and their beneficiaries, from experiencing what we have been through.”
  • The company’s lead MS drug candidate, Lucid‑MS, is described as a potentially game‑changing therapy that has shown reversal of nerve‑cell degradation in animal studies.

Notable Quotes

“We thank W5 for their important investigation into the illegal, but little known, practice of stock spoofing and some of its harmful effects on retail investors.” – Zeeshan Saeed, CEO

Materiality Assessment: Non-Material – Neutral (the release is primarily a public‑relations announcement about media coverage of ongoing litigation; no new financial or operational data disclosed).

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other